NCT02767661View on ClinicalTrials.gov

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Breast Cancer
Interventions
DRUG

Capecitabine

Capecitabine, 500mg, orally three times daily (continuously)

DRUG

Aromatase Inhibitor

Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)

Trial Locations (1)

510060

State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER